GL
BMY icon

Graypoint LLC’s Bristol-Myers Squibb BMY Stock Holding History

Graypoint LLC’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$635K Sell
13,721
-5,700
-29% -$280K 0.04% 287
2025
Q1 		$1.18M Buy
19,421
+3,423
+21% +$200K 0.07% 175
2024
Q4 		$905K Buy
15,998
+4,705
+42% +$263K 0.05% 207
2024
Q3 		$584K Buy
11,293
+2,563
+29% +$120K 0.04% 271
2024
Q2 		$363K Sell
8,730
-4,912
-36% -$220K 0.03% 346
2024
Q1 		$740K Sell
13,642
-133
-1% -$6.78K 0.05% 217
2023
Q4 		$707K Buy
13,775
+1,848
+15% +$97K 0.06% 205
2023
Q3 		$692K Buy
11,927
+2,767
+30% +$170K 0.07% 192
2023
Q2 		$586K Sell
9,160
-2,161
-19% -$145K 0.06% 195
2023
Q1 		$785K Buy
11,321
+3
+0% +$212 0.09% 154
2022
Q4 		$814K Sell
11,318
-1,625
-13% -$123K 0.1% 141
2022
Q3 		$920K Buy
12,943
+4,511
+53% +$327K 0.12% 128
2022
Q2 		$649K Buy
8,432
+581
+7% +$44.3K 0.08% 159
2022
Q1 		$573K Buy
7,851
+63
+0.8% +$4.23K 0.06% 189
2021
Q4 		$486K Sell
7,788
-124
-2% -$7.27K 0.05% 201
2021
Q3 		$468K Sell
7,912
-1,286
-14% -$84.7K 0.06% 173
2021
Q2 		$615K Buy
9,198
+776
+9% +$50.6K 0.08% 149
2021
Q1 		$532K Buy
8,422
+560
+7% +$34.8K 0.08% 156
2020
Q4 		$488K Buy
7,862
+280
+4% +$17.2K 0.08% 145
2020
Q3 		$457K Buy
7,582
+2,666
+54% +$160K 0.09% 137
2020
Q2 		$289K Buy
4,916
+25
+0.5% +$1.5K 0.07% 134
2020
Q1 		$272K Buy
+4,891
New +$299K 0.08% 126

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Graypoint LLC's BMY Position: Q2 2025 in Review

Graypoint LLC reduced its Bristol-Myers Squibb (BMY) stake by 29% in Q2 2025, selling an estimated $280K and leaving 13,721 shares worth $635K. The position accounts for 0.04% of the portfolio, ranked #287.

Graypoint LLC first reported a position in BMY in Q1 2020 and has held it in 22 quarters since. The position peaked at $1.18M in Q1 2025. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Graypoint LLC held 13,721 shares of Bristol-Myers Squibb worth $635K as of Q2 2025.
  • Graypoint LLC sold 5,700 Bristol-Myers Squibb shares in Q2 2025, an estimated $280K.
  • Bristol-Myers Squibb made up 0.04% of Graypoint LLC's portfolio in Q2 2025, its #287 holding.
  • Graypoint LLC first reported a position in Bristol-Myers Squibb in Q1 2020 and has held it in 22 quarters since.
  • Graypoint LLC's Bristol-Myers Squibb position peaked at $1.18M in Q1 2025.
  • 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.